Navigation Links
Otonomy Presents Positive New Findings From Phase 1b Study of OTO-104 in Meniere's Disease at International Conference
Date:9/29/2011

e impact of tinnitus on activities of daily living. Both OTO-104 doses resulted in reductions in THI Total Score from baseline as early as one month following treatment.  Furthermore, these THI Total Scores continued to decrease throughout the entire three month follow-up period, suggesting continued improvement in tinnitus symptoms experienced by patients treated with OTO-104.  By contrast, the study's placebo group demonstrated little change in THI Total Score from baseline during the three month follow-up period.  

As previously reported, results from this study showed OTO-104 to be safe and well-tolerated at both doses tested when delivered via a single IT injection.  It is important to note that despite demonstrating meaningful clinical activity in the areas of vertigo and tinnitus, this study was not powered to demonstrate statistical significance.  Based on these study results, Otonomy will initiate a Phase 2 clinical trial of OTO-104 in Meniere's disease during the fourth quarter of 2011.

"These new results provide the first demonstration of OTO-104's clinical activity in a cohort of Meniere's disease patients experiencing frequent vertigo episodes," stated Paul R. Lambert, M.D., professor and chair of the department of otolaryngology – head and neck surgery, Medical University of South Carolina, and the study's lead investigator.  "Furthermore, the continued reduction in vertigo frequency and improvement in tinnitus symptoms for the 12 mg OTO-104 group observed through three months of follow-up provides a strong rationale for initiating broader clinical evaluations of this sustained release product."

A total of 44 patients with unilateral Meniere's disease were enrolled in this prospective, randomized, double-blind, placebo-controlled multicenter study.  Patients participated in a one-month baseline period to characterize disease status, followed by randomization to receive a single IT injection
'/>"/>

SOURCE Otonomy, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Otonomy Introduces Scientific Advisory Board
2. Otonomys OTO-104 Demonstrates Hearing Loss Protection and Hearing Recovery in Preclinical Studies
3. Otonomy Appoints Gerald Wroblewski as Chief Operations Officer
4. Bluestar Silicones Presents Adhesive Gels for Wound Care at Medical Grade Polymers Conference
5. Acologix Presents Preclinical Data on Cartilage Regeneration by AC-100 at the 30th ASBMR Annual Meeting
6. Enobia Pharma Presents PreClinical Data Showing ENB-0040 Significantly Improved Survival and Healed Skeletal Manifestations of Severe Hypophosphatasia in Mice
7. MedImmune Presents Data at AAP National Conference & Exhibition Demonstrating Burden of RSV Disease
8. GeoVax Presents Data at AIDS Vaccine 2008 Conference
9. Dendreon Presents Preclinical Data Validating Anti-Tumor Activity of D-3263, a Trp-p8 Agonist
10. MedImmune Presents Data Highlighting its Progressive Inflammatory Disease Portfolio at the 72nd Annual Meeting of the American College of Rheumatology
11. Northern Antibiotics Presents New Data on Novel Polymyxin Compounds at the Joint ICAAC/IDSA 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... 11, 2014 /CNW/ - Sunovion Pharmaceuticals Canada Inc. (Sunovion) ... (eslicarbazepine acetate) for use as a once-daily adjunctive therapy ... epilepsy who are not satisfactorily controlled with conventional therapy. ... patients under 18 years of age. ... and according to Epilepsy Canada, it affects 0.6% of ...
(Date:7/10/2014)... Deep Knowledge Ventures last week sponsored ... Longevity Research’ and welcomed a host of London-based ... Innovation Center for the event, organised by the ... The meeting highlighted the need for both philanthropic ... disease, as well as the crucial role of ...
(Date:7/10/2014)... OMICS Group’s 5th International conference and ... 2014 at Double Tree by Hilton Beijing, China is ... Analytical & Bioanalytical research methods only to facilitate improved ... occasion, Dr. Srinubabu Gedela, MD of OMICS Group Inc ... remarkable one in bringing a unique and international mix ...
(Date:7/10/2014)... -- Kainos Capital, a firm specializing in acquiring and managing ... acquired the Slim-Fast brand from Unilever. Unilever will retain ... transaction were not disclosed. Slim-Fast is a ... ready-to-drink shakes, powders, bars and snacks to retail customers ... the United Kingdom and Ireland.  ...
Breaking Biology Technology:Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Approval of APTIOM(TM) (eslicarbazepine acetate) as a Once-Daily Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy 2Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Approval of APTIOM(TM) (eslicarbazepine acetate) as a Once-Daily Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy 3Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Approval of APTIOM(TM) (eslicarbazepine acetate) as a Once-Daily Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy 4DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 2DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 3DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 4DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 5DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 6A Critical Review of Analytical Techniques for Improved Living Standards 2A Critical Review of Analytical Techniques for Improved Living Standards 3A Critical Review of Analytical Techniques for Improved Living Standards 4Kainos Capital Acquires Slim-Fast From Unilever 2
... , , BOTHELL, ... BLFS), a leading manufacturer and marketer of biopreservation tools for ... into a non-exclusive distribution agreement with STEMCELL Technologies, Inc., based ... StemCell Group of companies, is a leading provider of products ...
... international ports could be the most affordable approach to ... not carrying nuclear bombs, according to a paper being ... the Institute for Operations Research and the Management Sciences ... in place that relies on targeting only a small ...
... and Washington DC (July 27, 2009) According to a ... Making , a large-scale, covert anthrax attack on a ... extremely effective public health response, primarily because of expected ... to it. The article "Predicting Hospital Surge after ...
Cached Biology Technology:BioLife Solutions and STEMCELL Technologies Announce Worldwide Distribution Agreement 2BioLife Solutions and STEMCELL Technologies Announce Worldwide Distribution Agreement 3Study on keeping nuclear bombs from US ports shows misplaced fear over cargo scanning cost 2Study on keeping nuclear bombs from US ports shows misplaced fear over cargo scanning cost 3Study on keeping nuclear bombs from US ports shows misplaced fear over cargo scanning cost 4Bioterrorism and disaster preparedness explored in special issue of Medical Decision Making 2
(Date:7/10/2014)... July 7, 2014 According to ... "Electronic Access Control Systems Market Global Forecast, Market Share, ... global Electronic Access Control systems market was valued at ... grow at a CAGR of 12.6% from 2014 to ... million in 2019. Browse the full Electronic ...
(Date:7/10/2014)... NORTHFIELD, Ill. , July 9, 2014 /PRNewswire-USNewswire/ ... record (EHR), spurred in large part by meaningful ... way health care providers interact with laboratory information. ... well-versed in the field of clinical informatics in ... care. To address the educational needs ...
(Date:7/10/2014)... German . An ... a central step of photosynthesis in action for the first ... State University used the world,s most powerful X-ray flashlight at ... of a molecular complex called photosystem II as it splits ... oxygen in earth,s atmosphere. The researchers report their results in ...
Breaking Biology News(10 mins):Electronic Access Control Systems Market is Expected to Reach USD 31.2 Billion Globally in 2019: Transparency Market Research 2Electronic Access Control Systems Market is Expected to Reach USD 31.2 Billion Globally in 2019: Transparency Market Research 3Electronic Access Control Systems Market is Expected to Reach USD 31.2 Billion Globally in 2019: Transparency Market Research 4Electronic Access Control Systems Market is Expected to Reach USD 31.2 Billion Globally in 2019: Transparency Market Research 5New Clinical Informatics Curriculum Prepares Future Pathologists 2New Clinical Informatics Curriculum Prepares Future Pathologists 3New Clinical Informatics Curriculum Prepares Future Pathologists 4Scientists watch photosynthesis in action 2Scientists watch photosynthesis in action 3
... a common feature in IBS and in fact may be ... on a lactulose breath test may indicate SIBO. Antibiotics and ... SIBO, but the efficacy of probiotics is untested. A pilot ... Shirota (Yakult(R)) on intestinal fermentation patterns of IBS patients. After ...
... interoperability during ePassports EAC ... Interoperability Tests in Prague, DALLAS, Sept. 9 ... Slovenia again has,selected Entrust, Inc. (Nasdaq: ENTU ) ... based on the Extended,Access Control (EAC) standard. With this, ...
... its intellectual and innovative strengths the betterment of the ... the betterment of us all. According to its ... Property and Commercialization shows that the institution continues to ... productivity and delivering new ideas to the marketplace. ...
Cached Biology News:Is yakult helpful in the treatment of irritable bowel syndrome? 2Entrust Expands Relationship with Slovenia, Implements Second-generation ePassport Solution 2Entrust Expands Relationship with Slovenia, Implements Second-generation ePassport Solution 3Entrust Expands Relationship with Slovenia, Implements Second-generation ePassport Solution 4Entrust Expands Relationship with Slovenia, Implements Second-generation ePassport Solution 5A reputation for innovation 2
Human HAPLN1 MAb (Clone 316119) Protein Family: Hyaluronan (HA) & HA Binding Proteins, Proteoglycan Regulators...
Reacts with MBP from human, bovine and rat, epitope 129-138. Reacts weakly with rabbit. Does not react with guinea pig....
SEQUENASE PCR PRODUCT PRE-SEQU, 1 EA. Category: SEQUENASE....
Cyno macaque plasma and serum - various quantities available...
Biology Products: